Abstract
Heart failure remains the main cause of death in children with heart disease. In USA and Europe hospital mortality of children with heart failure is about 7% of children, nearly twice as high as in adults. In this review a group of authors report about their experience with beta-blockers in childhood heart failure. Most of them start to treat children with severe heart failure at a time - 20 years ago - when beta blockers seem to be contraindicated in this situation. The physicians and their patients and/or parents all are aware of the risk of this decision. However, unproven medical therapies for heart failure are the most important therapeutical dilemma in pediatric cardiology. The authors carefully observed a highly selected group of patients with the highest risk to die and had the patience to wait for the longtime follow up. Today - based upon this experience –we know that beta blockers are safe and may save the lives of many children with heart disease all over the world. Together with young colleagues who enthusiastically support this idea the authors now intend to break down the “wall of ignorance” for this promising therapy in pediatric cardiology.
Keywords: Beta-blockers, childhood, duchenne, heart failure, hypertrophic cardiomyopathy, sudden death.
Reviews on Recent Clinical Trials
Title:Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Volume: 9 Issue: 2
Author(s): Reiner Buchhorn and Robert D. Ross
Affiliation:
Keywords: Beta-blockers, childhood, duchenne, heart failure, hypertrophic cardiomyopathy, sudden death.
Abstract: Heart failure remains the main cause of death in children with heart disease. In USA and Europe hospital mortality of children with heart failure is about 7% of children, nearly twice as high as in adults. In this review a group of authors report about their experience with beta-blockers in childhood heart failure. Most of them start to treat children with severe heart failure at a time - 20 years ago - when beta blockers seem to be contraindicated in this situation. The physicians and their patients and/or parents all are aware of the risk of this decision. However, unproven medical therapies for heart failure are the most important therapeutical dilemma in pediatric cardiology. The authors carefully observed a highly selected group of patients with the highest risk to die and had the patience to wait for the longtime follow up. Today - based upon this experience –we know that beta blockers are safe and may save the lives of many children with heart disease all over the world. Together with young colleagues who enthusiastically support this idea the authors now intend to break down the “wall of ignorance” for this promising therapy in pediatric cardiology.
Export Options
About this article
Cite this article as:
Buchhorn Reiner and Ross D. Robert, Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease), Reviews on Recent Clinical Trials 2014; 9 (2) . https://dx.doi.org/10.2174/157488710902141009103818
DOI https://dx.doi.org/10.2174/157488710902141009103818 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adjuvant Therapies of COVID-19 - A Literature Review
Coronaviruses Preoperative and Follow up Multi-Detector Row CT Angiography (MDCTA) in the Evaluation of Interrupted Aortic Arch (IAA)
Current Medical Imaging Job Stress and Blood Pressure: A Critical Appraisal of Reported Studies
Current Hypertension Reviews Markers of Early Vascular Ageing
Current Pharmaceutical Design Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Endothelial to Mesenchymal Transition in the Cardiogenesis and Cardiovascular Diseases
Current Cardiology Reviews Nonbacterial Thrombotic Endocarditis (Marantic Endocarditis) in Cancer Patients
Cardiovascular & Hematological Disorders-Drug Targets What We Learnt from Randomized Clinical Trials and Cohort Studies of Antioxidant Vitamin? : Focus on Vitamin E and Cardiovascular Disease
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Global Trends in Nanotechnological Approaches for Various Health Issues – Volume II)
Current Drug Metabolism Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations
Current Clinical Pharmacology Management of Asymptomatic Severe Aortic Stenosis
Current Cardiology Reviews Association between Paraoxonase 1(PON1) Gene Polymorphisms and PON1 Enzyme Activity in Indian Patients with Coronary Artery Disease (CAD)
Current Pharmacogenomics and Personalized Medicine Massively Parallel Screening of the Receptorome
Combinatorial Chemistry & High Throughput Screening Coumarin Compounds in Medicinal Chemistry: Some Important Examples from the Last Years
Current Topics in Medicinal Chemistry Recent Research Progress in Natural Bioactive Constituents against Lipid Metabolic Diseases
Current Topics in Medicinal Chemistry An Update to Enterococcal Bacteremia: Epidemiology, Resistance, and Outcome
Infectious Disorders - Drug Targets Recent Advances in the Discovery and Development of Marine Natural Products with Cardiovascular Pharmacological Effects
Mini-Reviews in Medicinal Chemistry Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders From Antidepressant Drugs to Beta-Mimetics: Preclinical Insights on Potential New Treatments for Neuropathic Pain
Recent Patents on CNS Drug Discovery (Discontinued) Selective Removal of Macrophages in Atherosclerotic Plaques as a Pharmacological Approach for Plaque Stabilization: Benefits Vs. Potential Complications
Current Vascular Pharmacology